PMGC Holdings Inc. announced on January 30, 2025, that its subsidiary, Northstrive Biosciences Inc., signed a research agreement with a leading preclinical contract research organization (CRO). This agreement supports a planned study to evaluate EL-32, a potential breakthrough obesity therapy.
EL-32 is an engineered probiotic expressing dual myostatin and activin-A inhibitors, focusing on two clinically validated targets for muscle regulation. The study will evaluate EL-32 both as a monotherapy and in combination with the GLP-1 receptor agonist semaglutide.
The focus of the preclinical study will be on glycemic control and body composition in diet-induced obese (DIO) mice. This research aims to advance EL-32 towards an Investigational New Drug (IND) application, building on encouraging past preclinical data.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.